Data protection Impressum

Newsroom

Relief Therapeutics has entered into an agreement with SWK Funding LLC to secure up to USD 11 million in non-dilutive financing through the sale of royalty interests to support its clinical development pipeline.

Geneva biotech Relief Therapeutics raises up to USD 11 million from royalty sales

14 August 2024

SWISSto12, an EPFL spin-off and leader in satellite and Radio Frequency (RF) products, has secured a USD 10 million contract to supply next-generation RF equipment to a European aeronautical OEM, enhancing safety at sea.

SWISSto12 secures USD 10 million contract for maritime safety technology

13 August 2024

DemoSquare has successfully raised CHF 1.2 million in pre-seed funding to fuel its expansion into European markets, aiming to enhance its AI-based platform for monitoring political and regulatory activities.

DemoSquare secures CHF 1.2 million for the expansion of its AI-based platform

13 August 2024

Release Therapeutics has raised CHF 3.3 million in seed funding to advance its innovative approach to treating metachromatic leukodystrophy (MLD), a rare genetic disorder affecting young children.

Release Therapeutics secures CHF 3.3 million to advance MLD research

13 August 2024

Meyer Burger Technology AG and Solestial Inc. have signed a strategic partnership to produce ultra-thin silicon solar cells for space applications.

Meyer Burger and Solestial partner to develop next generation space solar cells

12 August 2024

CSEM, along with start-ups Impli and Yalosys, has developed CERES, an implantable biosensor for real-time fertility hormone monitoring.

CSEM develops a pioneering implant to support reproductive medicine

7 August 2024

Oryl Photonics has joined the Fast and Accurate Solubility for Sustainability (FASS) project, receiving a EUR 2.5 million EIC Transition grant to develop a novel laboratory instrument for drug solubility measurement.

EPFL spin-off Oryl Photonics joins a EUR 2.5 million European project

7 August 2024

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

NOA by biped marks successful market entry in Europe and the US

6 August 2024

Technis, a Vaud-based scale-up, will deploy its advanced crowd management solutions at key sites for the Paris 2024 Olympics.

EPFL spin-off Technis to manage crowd flows at Paris 2024 Olympics

6 August 2024

1 … 24 25 26 27 28 29 30 31 32 … 143